IP Library › Granted Patent US 12698312
Granted Patent B2
US 12698312 · App. 17/998,411 · Granted Aug 4, 2026

JNK3 inhibitory peptides

Inventors: Tiziana Borsello (Milan, IT); Mattia Falconi (Rome, IT); Daniele Di Marino (Ancona, IT)
Assignees: UNIVERSITA' DEGLI STUDI DI MILANO; UNIVERSITA' DEGLI STUDI DI ROMA “TOR VERGATA”; UNIVERSITA' POLITECNICA DELLE MARCHE
C07K14/4702A61K47/645A61P25/28C12Y207/11024
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698312
App. No.
17/998,411
Granted
Aug 4, 2026
Kind
B2
Abstract

The subject of the present invention is a peptide, natural or synthetic, which comprises an amino acid sequence that has at least 80% sequence identity with the sequence SDRSLHLEANEKGENVNVHVTKTRADKSKIKVSVRQYADINEKGEAQYKCPVAQLE (SEQ ID NO: 1). A further object of the present invention is said peptide which has at least 80% sequence identity with the sequence SEQ ID NO: 1 which is a JNK3 inhibitor for use in the prevention and/or treatment of neurodegenerative or neurodevelopmental diseases.

Claims (13)

1 . A peptide, natural or synthetic, comprising an amino acid sequence that has at least 80% sequence identity with the sequence

(SEQ ID NO: 1)

SDRSLHLEANEKGENVNVHVTKTRADKSKIKVSVRQYADINEKGEAQYK

CPVAQLE.

2 . The peptide according to claim 1 , which has at least 90% sequence identity with SEQ ID NO: 1.

3 . The peptide according to claim 1 , which has at least 95% sequence identity with SEQ ID NO: 1.

4 . The peptide according to claim 1 , which consists of SEQ ID NO: 1.

5 . The peptide according to claim 1 , which is conjugated to a polypeptide transport moiety.

6 . The peptide according to claim 5 , wherein said polypeptide transport moiety is TAT protein.

7 . A pharmaceutical composition comprising at least one peptide according to claim 1 and a pharmaceutically acceptable carrier.

8 . A method for treating an acute pathology of the nervous system of a subject, comprising administering an effective amount of a pharmaceutical composition comprising at least one peptide according to claim 6 and a pharmaceutically acceptable carrier to a subject in need thereof; wherein the acute pathology of the nervous system is selected from ischemia, traumatic brain injury, Alzheimer's, Parkinson's disease, Huntington's disease, frontotemporal dementia, Down syndrome, schizophrenia, spino-cerebellar ataxia, muscular atrophy, amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and prion diseases.

9 . The method according to claim 8 , wherein the acute pathology of the nervous system is Alzheimer's disease.

10 . The method according to claim 8 , wherein the acute pathology of the nervous system is traumatic brain injury.